The treatment of early parkinson's disease: Levodopa rehabilitated

Practical Neurology

Volumn 11, Issue 3, 2011, Pages 145-152

  Vlaar, Annemarie ^a   Hovestadt, A D ^b   van Laar, Teus ^c   Bloem, Bastiaan R ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ARTICLE; DRUG RESISTANCE; DYSKINESIA; HUMAN; METABOLISM; PARKINSON DISEASE; PHYSIOLOGY;

DOPAMINE AGENTS; DRUG RESISTANCE; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 79957652863     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2011-000011     Document Type: Article

References (33)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modif cation of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
2. Kurlan R. 'Levodopa phobia': a new iatrogenic cause of disability in Parkinson disease. Neurology 2005;64:923-924.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor f uctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
4. Clissold BG, McColl CD, Reardon KR, et al. Longitudinal study of the motor response to levodopain Parkinson's disease. Mov Disord 2006;21:2116-2121.
5. Van Gerpen JA, Kumar N, Bower JH, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209.
6. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005.
7. Kumar N, Van Gerpen JA, Bower JH, et al. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20:342-344.
8. Mouradian MM, Heuser IJ, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
9. Olanow CW, Lees A, Obeso J. Levodopa therapy for Parkinson's disease: challenges and future prospects. Mov Disord 2008;23(Suppl 3):S495-S496.
10. Bloem BR, Roos RA. Neurotoxicity of designer drugs and related compounds. In: Handbook of clinical neurology. Amsterdam: Elsevier 1995.
11. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
12. Kostić VS, Marinković J, Svetel M, et al. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 2002;9:9-14.
13. Kempster PA, Williams DR, Selikhova M, et al. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 2007;130:2123-2128.
14. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-1926.
15. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
16. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
17. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-1278.
18. Schapira AH. PROUD: the impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. Poster P1366 presented at the 12th EFNS Congress 2008, Madrid, Spain.
19. Bonnet AM, Loria Y, Saint-Hilaire MH, et al. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-1542.
20. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
21. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
22. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007;69:1701-1711.
23. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
24. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
25. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006;21:343-353.
26. Constantinescu R, Romer M, McDermott MP, et al. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007;22:1317-1319.
27. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71:474-480.
28. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov Disord 2007;22:1-9.
29. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
30. Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007;78:465-469.
31. Quinn NP. Lecture at retirement Festschrift. London 2007.
32. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
33. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-1062.